HW221043 / Humanwell Healthcare - LARVOL DELTA

Discovery of HW221043, a potent and orally bioavailable KIF18A inhibitor for treating chromosomal instability in cancer (AACR 2025) - "These findings provide pharmacological proof-of-concept for the synthetic lethal effect of HW221043 and support KIF18A inhibition as a novel therapeutic strategy in oncology. HW221043 is currently in the Investigational New Drug (IND) enabling stage of development."

Oncology • KIF18A